Molecular genetic basis of tuberous sclerosis complex: From bench to bedside

Journal of Child Neurology

Volumn 19, Issue 9, 2004, Pages 699-709

  Au, Kit Sing ^a   Williams, Aimee T ^a   Gambello, Michael J ^a   Northrup, Hope ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAMARTIN; TUBERIN;

AUTOSOMAL DOMINANT DISORDER; BENIGN TUMOR; FAMILY; GENE MUTATION; GENETIC COUNSELING; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MEDICAL CARE; MOLECULAR GENETICS; MOSAICISM; NONHUMAN; PATIENT CARE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS;

EID: 8844286824     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738040190091101     Document Type: Review

References (87)

1. Kirpicznik J: Ein fall von Tuberoser Sklerose and gleichzeitigen multiplen Nierengeschwulsten. Virchows Arch J Pathol Anat 1910;202(3):358.
2. Balzer F, Menetrier P: Etude sue un cas d'adenomes sebace de la face et du cuir chevelu. Arch Physiol Norm Pathol (sé rie III) 1885;6:564-576.
3. Pringle JJ: A case of congenital adenoma sebaceum. Br J Dermatol 1890;2:1-14.
4. Berg H: Vererbung der tuberosen Sklerose durch zweigzu drei Generationen. Z Gies Neurol Psychiatr 1913;19:528-539.
5. Gunther M, Penrose LS: The genetics of epiloia. J Genet 1935; 31:413-430.
6. Dickerson WW. Familial occurrence of tuberous sclerosis. AMA Arch Neurol Psychiatry 1951;65:683-702.
7. Lagos JC, Gomez MR: Tuberous sclerosis: Reappraisal of a clinical entity. Mayo Clin Proc 1967;42:26-49.
8. Borberg A: Clinical and genetic investigations into tuberous sclerosis and Recklinghausen's neurofibromatosis; contribution to elucidation of interrelationship and eugenics of the syndromes. Acta Neurol Scand Suppl 1951;71:1-239.
9. Nevin NC, Pearce WG: Diagnostic and genetical aspects of tuberous sclerosis. J Med Genet 1968;5:273-280.
10. Zaremba J: Tuberous sclerosis: A clinical and genetical investigation. J Ment Defic Res 1968;12:63-80.
11. Bundey S, Evans K: Tuberous sclerosis: A genetic study. J Neurol Neurosurg Psychiatry 1969;32:591-603.
12. Singer K; Genetic aspects of tuberous sclerosis in a Chinese population. Am J Hum Genet 1971;23:33-40.
13. Hunt A, Lindenbaum RH: Tuberous sclerosis: A new estimate of prevalence within the Oxford region. J Med Genet 1984;21:272-277.
14. Wiederholt WC, Gomez MR, Kurland LT: Incidence and prevalence of tuberous sclerosis in Rochester, Minnesota, 1950 through 1982. Neurology 1985;35:600-603.
15. Sampson JR, Yates JRW, Pirrit LA, et al: Evidence for genetic heterogeneity in tuberous sclerosis. J Med Genet 1989;26:511-516.
16. Shepherd CW, Beard CM, Gomez MR, et al: Tuberous sclerosis complex in Olmsted County, Minnesota, 1950-1989. Arch Neurol 1991;48:400-401.
17. Stevenson AC, Fisher OD: Frequency of epiloia in Northern Ireland. Br J Prev Soc Med 1956;10:134-135.
18. Fryer AE, Chalmers A, Connor JM, et al: Evidence that the gene for tuberous sclerosis is on chromosome 9. Lancet 1987;i:659-661.
19. Northrup H., Beaudet AL, O'Brien WE, et al: Linkage of tuberous sclerosis to ABO blood group. Lancet 1987;ii:804-805.
20. Povey S, Burley MW, Fryer AE, et al: Genetic recombination between tuberous sclerosis and oncogene v-abl. Lancet 1988;ii:279-280.
21. Janssen, LA, Sandkuyl LA, Merkens EC, et al: Genetic heterogeneity in tuberous sclerosis. Genomics 1990;8:237-242.
22. Northrup H., Kwiatkowski DJ, Roach ES, et al: Evidence for genetic heterogeneity in tuberous sclerosis: One locus on chromosome 9 and at least one locus elsewhere. Am J Hum Genet 1992;51:709-720.
23. Kandt RS, Haines JL, Smith M, et al: Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. Nat Genet 1992;2:37-41.
24. European Chromosome 16 Tuberous Sclerosis Consortium: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993;75:1305-1315.
25. Online Mendelian Inheritance in Man, 191092. Available at: http://www.ncbi.nlm.gov/entrez/query.fegi?db=omim, date accessed April 15, 2004.
26. Xu L, Sterner C, Maheshwar MM, et al: Alternative splicing of the tuberous sclerosis 2 (TSC2) gene in human and mouse tissues. Genomics 1995;27:475-480.
27. Online Mendelian Inheritance in Man, 191100. Available at: http://www.ncbi.nlm.gov/entrez/query.fegi?db=omim, date accessed April 15, 2004.
28. van Slegtenhorst M, de Hoogt R, Hermans C, et al: Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997;277:805-808.
29. Benvenuto G, Li S, Brown SJ, et al: The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 2000;19:6306-6316.
30. Hodges AK, Li S, Maynard J, et al: Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin. Hum Mol Genet 2001;10:2899-2905.
31. Mizuguchi M, Ikeda K, Takashima S: Simultaneous loss of hamartin and tuberin from the cerebrum, kidney and heart with tuberous sclerosis. Acta Neuropathol (Berl) 2000;99:503-510.
32. Yeung RS, Xiao GH, Jin F, et al: Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc Natl Acad Sci U S A 1994;91:11413-11416.
33. Kobayashi T, Hirayama Y, Kobayashi E, et al: A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat Genet 1995;9:70-74.
34. +/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 1999;104:687-695.
35. Kobayashi T, Minowa O, Kuno J, et al: Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 1999;59:1206-1211.
36. Kobayashi T, Minowa O, Sugitani Y, et al: A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc Natl Acad Sci U S A 2001;98:8762-8767.
37. Uhlmann EJ, Apicelli AJ, Baldwin RL, et al: Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2 /- cells. Oncogene 2002;21:4050-4059.
38. Gao X, Pan D: TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 2001;15:1383-1392.
39. Potter CJ, Huang H, Xu T: Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 2001;105:357-368.
40. Kenerson HL, Aicher LD, True LD, et al: Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002;62:5645-5650.
41. Tsuchiya H, Orimoto K, Kobayashi K, et al: Presence of potent transcriptional activation domains in the predisposing tuberous sclerosis (Tsc2) gene product of the Eker rat model. Cancer Res 1996;56:429-433.
42. Inoki K, Li Y, Zhu T, et al: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4:648-657.
43. Gao X, Zhang Y, Arrazola P, et al: Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 2002;4: 699-704.
44. Wienecke R, Konig A, DeClue JE: Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity. J Biol Chem 1995;270:16409-16414.
45. Xiao GH, Shoarinejad F, Jin F, et al: The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. J Biol Chem 1997;272: 6097-6100.
46. Castro AF, Rebhun JF, Clark GJ, et al: Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem 2003;278:32493-32496.
47. Garami A, Zwartkruis FJ, Nobukuni T, et al: Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 2003;11:1457-1466.
48. Inoki K, Li Y, Xu T, et al: Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003;17:1829-1834.
49. Tee AR, Anjum R, Blenis J: Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin. J Biol Chem 2003;278:37288-37296.
50. Zhang Y, Gao X, Saucedo LJ, et al: Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 2003;5:578-581.
51. Astrinidis A, Senapedis W, Coleman TR, et al: Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B. J Biol Chem 2003;278:51372-51379.
52. Jaeschke A, Hartkamp J, Saitoh M, et al: Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J Cell Biol 2002;159:217-224.
53. Shah OJ, Hunter T: Critical role of T-loop and H-motif phosphorylation in the regulation of S6 kinase 1 by the tuberous sclerosis complex. J Biol Chem 2004;279(20):10816-20823.
54. Lamb RF, Roy C, Diefenbach TJ, et al: The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol 2000;2:281-287.
55. Astrinidis A, Cash TP, Hunter DS, et al: Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene 2002; 21:8470-8476.
56. Li S, Braverman R, Li H, et al: Regulation of cell morphology and adhesion by the tuberous sclerosis complex (TSC1/2) gene products in human kidney epithelial cells through increased E-cadherin/beta-catenin activity. Mol Carcinog 2003;37:98-109.
57. Mak BC, Takemaru K, Kenerson HL, et al: The tuberin-hamartin complex negatively regulates beta-catenin signaling activity. J Biol Chem 2003;278:5947-5951.
58. Li Y, Inoki K, Vacratsis P, et al: The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3. J Biol Chem 2003;278: 13663-13671.
59. Nellist M, Goedbloed MA, Halley DJ: Regulation of tuberous sclerosis complex (TSC) function by 14-3-3 proteins. Biochem Soc Trans 2003;31(Pt 3):587-591.
60. Hengstschlager M, Rosner M, Fountoulakis M, et al: Regulation of PCNA and CAF-1 expression by the two tuberous sclerosis gene products. Biochem Biophys Res Commun 2003;307:737-742.
61. Govindarajan B, Mizesko MC, Miller MS, et al: Tuberous sclerosis-associated neoplasms express activated p42/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth. Clin Cancer Res 2003;9:3469-3475.
62. Yoon HS, Ramachandiran S, Chacko MA, et al: Tuberous sclerosis-2 tumor suppressor modulates ERK and B-Raf activity in transformed renal epithelial cells. Am J Physiol Renal Physiol 2004;286:F417-F424.
63. Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 1997;272:13-16.
64. Welsh CF: Rho GTPases as key transducers of proliferative signals in G1 cell cycle regulation. Breast Cancer Res Treat 2004;84:33-42.
65. Noonan DJ, Lou D, Griffith N, et al: A calmodulin binding site in the tuberous sclerosis 2 gene product is essential for regulation of transcription events and is altered by mutations linked to tuberous sclerosis and lymphangioleiomyomatosis. Arch Biochem Biophys 2002;398:132-140.
66. Finlay GA, York B, Karas RH, et al: Regulation of PDGF production and ERK activation by estrogen is associated with TSC2 gene expression. Am J Physiol Cell Physiol 2003;285:C409-C418.
67. Dabora SL, Jozwiak S, Franz DN, et al: Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001;68:64-80.
68. Green AJ, Sepp T, Yates JR: Clonality of tuberous sclerosis harmatomas shown by non-random X-chromosome inactivation. Hum Genet 1996;97:240-243.
69. Brook-Carter PT, Peral B, Ward CJ, et al.: Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease - a contiguous gene syndrome. Nat Genet 1994; 8:328-332.
70. Jones AC, Daniells CE, Snell RG, et al: Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. Hum Mol Genet 1997;6:2155-2161.
71. Jones AC, Shyamsundar MM, Thomas MW, et al: Comprehensive mutation analysis of TSC1 and TSC2 and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 1999;64:1305-1315.
72. Longa L, Saluto A, Brusco A, et al: TSC1 and TSC2 deletions differ in size, preference for recombinatorial sequences, and location within the gene. Hum Genet 2001;108:156-166.
73. Young J, Povey S: The genetic basis of tuberous sclerosis. Mol Med Today 1998;4:313-319.
74. Niida Y, Lawence-Smith N, Banwell A, et al: Analysis of both TSC1 and TSC2 for germline, mutations in 126 unrelated patients with tuberous sclerosis. Hum Mutat 1999;14:412-422.
75. van Slegtenhorst M, Verhoef S, Tempelars A, et al: Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: No evidence for genotype-phenotype correlation. J Med Genet 1999;36:285-289.
76. Al-Saleem T, Wessner LL, Scheithauer BW, et al: Malignant rumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer 1998;83:2208-2216.
77. Byers PH, Tsipouras P, Bonadio JF, et al: Perinatal lethal osteogenesis imperfecta (OI type II): A biochemically heterogeneous disorder usually due to a new mutation in the genes for type I collagen. Am J Hum Genet 1988;42:237-248.
78. Edwards JH: The population genetics of Duchenne: Natural and artificial selection in Duchenne muscular dystrophy. J Med Genet 1986;23:521-530.
79. Sippel KC, Fraioli RF, Smith GD, et al: Frequent somatic and germ-line mosaicism in retinoblastoma: Relevance to genetic counseling. Am J Hum Genet 1997;Suppl 61(4):A16.
80. Murgia A, Martella M, Vinanzi C, et al: Molecular analysis of the VHL gene: Somatic mosaicism in von Hippel-Lindau disease. Am J Hum Genet 1997;Suppl 61(4):A75.
81. Lazaro C, Ravella A, Gaona A, et al: Neurofibromatosis type I due to germ-line mosaicism in a clinically normal father. N Engl J Med 1994;331:1403-1407.
82. Sampson JR, Maheshwar MM, Aspinwall R, et al: Renal cystic disease in tuberous sclerosis: Role of the polycystic kidney disease 1 gene. Am J Hum Genet 1997;61:843-851.
83. Verhoef S, Vrtel R, van Essen T, et al: Somatic mosaicism and clinical variation in tuberous sclerosis complex. Lancet 1995; 345:202.
84. Rose VM, Au K-S, Pollom G, et al: Germ-line mosaicism in tuberous sclerosis: How common? Am J Hum Genet 1999;64: 986-992.
85. Yates JR, van Bakkel I, Sepp T, et al: Female germline mosaicism in tuberous sclerosis confirmed by molecular genetic analysis. Hum Mol Genet 1997;6:2265-2269.
86. Osborne JP, Jones AC, Burley MW, et al: Non-penetrance in tuberous sclerosis. Lancet 2000;355:1698.
87. Williams AT, Northrup H, Au K-S, et al: Genetic heterogeneity in a tuberous sclerosis family: Implications for genetic counseling. Am J Hum Genet 2003;73:362.